Diabetic Peripheral Neuropathy
Diabetic Peripheral Neuropathy Market

Diabetic Peripheral Neuropathy (DPN), also known as Distal symmetric polyneuropathy (DSPN), is defined as the symptoms of peripheral nerve dysfunction and nerve damage in diabetic patients after excluding other causes.


Diabetic peripheral neuropathy is one of the most common long-term complications of diabetes. It develops in up to half of all people with diabetes and is one of the main risk factors contributing to foot ulceration and eventual amputation. In diabetic neuropathy, several metabolic and vascular changes interconnect to cause damage to nerve cells in a similar way to that seen in diabetic retinopathy and nephropathy, with the primary underlying factor being hyperglycemia Changes include increased oxidative stress, a build-up of glycation end-products, increased activity of the polyol pathway, activation of proinflammatory mechanisms and ischemia. 


Diabetic Peripheral Neuropathy signs and symptoms include numbness, tingling, low balance, burning pain, electric shocks, stabbing, spontaneous pain at the affected site, hypersensitive to pain against nociceptive warmth stimulation, and others.


Diabetic Peripheral Neuropathy Epidemiological Segmentation 

The Epidemiological Segmentation of Diabetic Peripheral Neuropathy in 7MM from 2017 to 2030 is segmented as:- 

  • Total Diagnosed Prevalent Cases of DPN
  • Gender-specific Prevalent Cases of DPN
  • Total Prevalent Cases of Painful Diabetic Peripheral Neuropathy


Diabetic Peripheral Neuropathy Epidemiology 

  • The total diagnosed prevalent population of DPN in 7MM in 2017 was 25,332,829.
  • Among all the countries, the US had higher prevalent population cases of 12,522,483 in 2017.  


Diabetic Peripheral Neuropathy Market

Diabetic Peripheral Neuropathy Market Size in the 7MM in 2017 was USD 2,275.52 million. 


Diabetic Peripheral Neuropathy Emerging Drugs

The emerging drugs of the Diabetic Peripheral Neuropathy market are 

  • VM202 
  • NYX-2925 
  • WST-057 
  • Ricolinostat 
  • ISC 17536
  • NRD135S.E1
  • Cebranopadol 
  • GRC 17356 
  • MEDI7352
  • Trazodone/Gabapentin

And many others.  


Diabetic Peripheral Neuropathy Key Players

The key players in the Diabetic Peripheral Neuropathy market are

  • Helixmith
  • Aptinyx
  • WinSanTor, Inc
  • Regenacy Pharmaceuticals
  • Ichnos Science
  • Novaremed 
  • Gr√ľnenthal GmbH
  • Glenmark Pharmaceuticals
  • AstraZeneca
  • Angelini

And many others.